Published in AIDS on January 25, 2002
High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J Virol (2003) 2.04
The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. Int J Epidemiol (2013) 1.48
Geographic HIV type 1 subtype distribution in Rakai district, Uganda. AIDS Res Hum Retroviruses (2009) 1.22
Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans. PLoS One (2009) 0.97
HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men. PLoS Pathog (2014) 0.92
Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition. J Virol (2005) 0.92
The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. J Int AIDS Soc (2012) 0.85
Effect of HIV-1 subtypes on disease progression in rural Uganda: a prospective clinical cohort study. PLoS One (2013) 0.81
Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. J Acquir Immune Defic Syndr (2014) 0.77
HIV subtypes in Scotland, 2000-2006. Epidemiol Infect (2007) 0.76
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS (2002) 3.99
Interim smallpox guidelines for the United Kingdom. BMJ (2002) 3.14
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis (2002) 2.54
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis (2011) 2.32
Time for fair trade in research data. Lancet (2009) 2.29
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Impact of the HIV epidemic in sub-Saharan Africa on the pattern of HIV in the UK. AIDS (2003) 1.96
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine (2008) 1.89
Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis (2004) 1.76
HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sex Transm Infect (2011) 1.75
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol (2008) 1.71
Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis (2004) 1.67
Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr (2007) 1.64
HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses (2011) 1.63
High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis (2012) 1.62
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Associations between helminth infection and CD4+ T cell count, viral load and cytokine responses in HIV-1-infected Ugandan adults. Trans R Soc Trop Med Hyg (2003) 1.57
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS (2011) 1.44
Indigenous hepatitis E virus infection in England: more common than it seems. J Clin Virol (2009) 1.44
Rabies virus in a dog imported to the UK from Sri Lanka. Vet Rec (2008) 1.40
Early qualitative risk assessment of the emerging zoonotic potential of animal diseases. BMJ (2005) 1.38
Hepatitis E outbreak on cruise ship. Emerg Infect Dis (2009) 1.37
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36
Importation of multidrug-resistant Acinetobacter spp infections with casualties from Iraq. Lancet Infect Dis (2006) 1.31
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr (2006) 1.29
High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda. J Int AIDS Soc (2013) 1.28
Treatment of Schistosoma mansoni infection increases helminth-specific type 2 cytokine responses and HIV-1 loads in coinfected Ugandan adults. J Infect Dis (2005) 1.24
Short communication: High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses (2012) 1.23
Surveillance methods to monitor the impact of HIV therapy programmes in resource-constrained countries. AIDS (2005) 1.18
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Indigenous hepatitis E in England and wales from 2003 to 2012: evidence of an emerging novel phylotype of viruses. J Infect Dis (2013) 1.15
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One (2008) 1.15
The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem (2004) 1.13
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest (2014) 1.12
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis (2013) 1.12
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11
Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis (2005) 1.10
Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Trans R Soc Trop Med Hyg (2004) 1.09
First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ (2002) 1.06
The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis. AIDS Care (2009) 1.06
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses (2010) 1.04
Hepatitis E in England and Wales. Emerg Infect Dis (2008) 1.04
Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults. Trop Med Int Health (2009) 1.03
Schistosoma mansoni, nematode infections, and progression to active tuberculosis among HIV-1-infected Ugandans. Am J Trop Med Hyg (2006) 1.02
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr (2010) 1.01
Investigating the empirical evidence for understanding vulnerability and the associations between poverty, HIV infection and AIDS impact. AIDS (2007) 1.01
Strongyloides stercoralis hyperinfection in a patient with AIDS in Uganda successfully treated with ivermectin. Clin Infect Dis (2003) 1.01
Sexually transmitted disease management in Uganda's private-for-profit formal and informal sector and compliance with treatment. Sex Transm Dis (2004) 1.00
Using verbal autopsy to assess the prevalence of HIV infection among deaths in the ART period in rural Uganda: a prospective cohort study, 2006-2008. Popul Health Metr (2011) 1.00
Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda. Vaccine (2013) 0.99
The relationship between HIV type 1 disease progression and V3 serotype in a rural Ugandan cohort. AIDS Res Hum Retroviruses (2004) 0.98
Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. AIDS Res Hum Retroviruses (2007) 0.98
HIV-1 transmission within marriage in rural Uganda: a longitudinal study. PLoS One (2013) 0.97
Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans. PLoS One (2009) 0.97
Money, men and markets: economic and sexual empowerment of market women in southwestern Uganda. Cult Health Sex (2005) 0.97
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob Agents Chemother (2011) 0.96
HIV-1 subtype dynamics over 10 years in a rural Ugandan cohort. Int J STD AIDS (2004) 0.95
HIV vaccines: current status worldwide and in Africa. AIDS (2010) 0.94
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther (2012) 0.94
Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology (2011) 0.93
Killer cell immunoglobulin-like receptor (KIR) genes and their HLA-C ligands in a Ugandan population. Immunogenetics (2013) 0.93
EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. BMC Public Health (2013) 0.93
Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria. AIDS Res Hum Retroviruses (2013) 0.91
Eosinophilia and progression to active tuberculosis in HIV-1-infected Ugandans. Trans R Soc Trop Med Hyg (2004) 0.91
HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans. AIDS Res Hum Retroviruses (2004) 0.90
Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90
Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis (2004) 0.90
The role of community acceptance over time for costs of HIV and STI prevention interventions: analysis of the Masaka Intervention Trial, Uganda, 1996-1999. Sex Transm Dis (2006) 0.89
Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol (Oxf) (2013) 0.89
An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries. AIDS (2010) 0.88
Effects of cotrimoxazole on hematologic parameters in HIV-infected adults in a community-based clinic in Entebbe, Uganda. J Acquir Immune Defic Syndr (2007) 0.88
Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naive population in rural southwestern Uganda. AIDS Res Hum Retroviruses (2006) 0.88
Human immunodeficiency virus type 1 Western blot: revised diagnostic criteria with fewer indeterminate results for epidemiological studies in Africa. Int J Epidemiol (2002) 0.88
Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects. J Leukoc Biol (2005) 0.87
Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners. J Virol (2013) 0.87
Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine (2004) 0.87
Impairment of the Schistosoma mansoni-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection. J Infect Dis (2004) 0.86
Low drug resistance levels among drug-naive individuals with recent HIV type 1 infection in a rural clinical cohort in southwestern Uganda. AIDS Res Hum Retroviruses (2012) 0.86